Type one macular neovascularization in central serous chorioretinopathy: Short-term response to anti-vascular endothelial growth factor therapy

Abstract

The aim of this study was to assess the short-term effect of anti-vascular endothelial growth factor (VEGF) treatment on type 1 macular neovascularization (MNV) secondary to central serous chorioretinopathy (CSCR) and to identify potential predictive factors for treatment response using multimodal imaging. Retrospective, multicentre study in CSCR patients with MNV detected by OCT-angiography and treated with anti-VEGF injections. Clinical and multimodal imaging data before and after anti-VEGF injections was reviewed. Univariate and multivariate linear regression analyses were performed to evaluate associations between the change in central macular thickness (CMT) after anti-VEGF therapy and other factors. Forty patients were included. One month after receiving a mean number of 2.7 anti-VEGF intravitreal injections, visual acuity increased significantly from 0.46\u2009±\u20090.3 logMAR at baseline to 0.38\u2009±\u20090.4 logMAR (p\u2009=\u20090.04). The CMT and foveal serous retinal detachment (SRD) decreased significantly from 330\u2009±\u200981.9\u2009µm at baseline to 261.7\u2009±\u200963.1\u2009µm after treatment (p\u2009<\u20090.001) and from 145.1\u2009±\u200998.8\u2009µm at baseline to 52.6\u2009±\u200971.3\u2009µm (p\u2009<\u20090.001), respectively. Subretinal fluid and/or intraretinal fluid were still present in 18 eyes (45%) one month after treatment. In the multivariate analysis, a higher SRD height was associated with a greater CMT change (p\u2009=\u20090.002) and a lower CMT change with the presence of subretinal hyperreflective material (SHRM) (p\u2009=\u20090.04). Fluid resorption was incomplete in about half of the patients with MNV secondary to CSCR after anti-VEGF injections. Shallower SRD or the presence of SHRM were predictors of poor response to anti-VEGF.